Search

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

EHA-SWG Scientific Meetings

On this page, you can browse and/or download the interactive EHA-SWG Scientific Meetings Sponsor Program.

Read more

5th Focus in Paediatric Haematology-Oncology

The course, which is particularly aimed at specialist trainees in pediatric haemato-oncology, continued the same ethos which inspired the first four courses: the importance of close interactions between the participants and the teaching faculty, a strong emphasis on real cases…

Read more

“Follow your dreams! Go for it!” – Verena Gaidzik, woman in hematology/EHA volunteer

Verena Gaidzik is a physician scientist in the department of Internal Medicine III (Head: Prof. Dr. Hartmut Döhner) at the University Hospital of Ulm. She has board certifications in internal medicine, hematology and oncology as well as palliative medicine.

Read more

EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

Join us for this unique and rare opportunity and exchange ideas with MDS, MPN, and AML experts in one meeting. Internationally renowned experts will provide presentations and share the recent developments and answers to your clinical questions.

Read more

EHA Statement on COVID-19

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

EHA Taskforce on Diversity, Equity, and Inclusion

The Diversity, Equity, and Inclusion Taskforce has a mandate from the EHA Board to develop a policy on Diversity, Equity, and Inclusion that will be the blueprint for:

Initiating and implementing activities to empower underrepresented groups.

Read more